How Many People Have Pacemakers? Statistics & Trends

Millions of people worldwide live with implanted pacemakers, and the numbers keep climbing. In the United States alone, roughly 2.9 million pacemaker implantations were performed between 1993 and 2009, with annual procedures rising from about 121,300 to 188,700 over that period. The global picture is harder to pin down because implantation rates vary wildly from country to country, but in high-income nations the rate sits somewhere between 300 and 1,200 implantations per million people each year, while in many low- and middle-income countries the rate can be as low as 1 to 7 per million.

How Many Americans Have Pacemakers Right Now

The most cited U.S. prevalence estimate comes from national health survey data that found roughly 456,000 noninstitutionalized adults living with pacemakers, translating to about 2.6 per 1,000 people.¹ That survey is now dated, and given that annual implantation rates have roughly doubled since it was conducted, the true number of Americans currently living with a pacemaker is almost certainly well north of one million. Between 1993 and 2009, the U.S. implantation rate rose from about 47 per 100,000 people to nearly 62 per 100,000.² Population-based data from Olmsted County, Minnesota, show an even steeper trajectory, with adjusted implant rates climbing from about 37 per 100,000 person-years in the late 1970s to roughly 99 per 100,000 by the early 2000s.³

The upward trend reflects more than just population growth. Devices got smaller and safer, guidelines broadened the conditions eligible for pacing, and average life expectancy increased, meaning more people live long enough to develop the heart-rhythm problems that call for a pacemaker. These factors compound: more eligible patients, more confidence among physicians, and better outcomes all push implantation numbers higher year after year.

Who Gets a Pacemaker

Pacemakers are overwhelmingly a device for older adults. Prevalence climbs steeply with age: among people 18 to 64 years old in the U.S., the rate is only about 0.4 per 1,000, but among those 75 and older it jumps to about 26 per 1,000.¹ Data from the U.K. show that prevalence among people over 75 has exceeded 2,000 per 100,000 since the mid-2000s.⁴ Among Medicare beneficiaries in the U.S., implantation rates per 100,000 rose from about 227 in the 65-to-74 age group to nearly 586 in the 75-to-84 group and 875 in the 85-to-94 group, before dropping off slightly among those over 94.⁵

Men receive pacemakers more often than women. Czech registry data covering more than a decade show that about 57% of first implants go to men, and that share has been inching upward over time. The average age at first implantation in that registry was 76 years, with women tending to be about two years older than men at the time of surgery.⁶ The age-adjusted implantation rate for men was about 70% higher than for women in older U.S. population data.⁵ Not every registry skews male, though: a study from Iran found 53% of pacemaker recipients were female, with a lower average age at implantation (mid-60s), which may reflect differences in referral patterns, disease mix, or population demographics.⁷

Why Pacemakers Are Implanted

The two big reasons are sinus node disease and atrioventricular block. Sinus node disease, where the heart’s natural pacemaker fires too slowly or erratically, accounts for about half of all implants in many centers. Two separate hospital studies found the condition behind roughly 53% and 52.5% of permanent pacemaker procedures, respectively.⁸⁹ Atrioventricular block, where electrical signals between the upper and lower chambers of the heart are delayed or blocked entirely, is the second most common reason. In some settings the proportions flip: a 10-year series from Nigeria found complete heart block as the leading indication in about 61% of cases, followed by second-degree block in another 27%.¹⁰ The mix of indications depends partly on local referral patterns and partly on how advanced a patient’s disease is by the time they reach an electrophysiologist.

The Enormous Gap Between Rich and Poor Countries

The starkest trend in global pacemaker use is the gap between wealthy and lower-income nations. High-income countries implant pacemakers at rates of 300 to 1,200 per million people, while in parts of sub-Saharan Africa, South Asia, and Southeast Asia the rate drops to as low as 1 to 7 per million.¹¹ The implication is grim: hundreds of thousands of people in low- and middle-income countries die preventable deaths each year because they cannot access a device that is routine elsewhere.¹¹

Even within wealthier regions, the differences are striking. A systematic review of European implant data found that the ratio between the highest- and lowest-implanting countries ranged from about 2 to 88 for pacemakers alone. That variation appears to be driven by a mix of healthcare system capacity, reimbursement policies, the number of trained electrophysiologists, and cultural attitudes toward device therapy.¹² Within the same country, regional implant rates can differ by a factor of three or more, suggesting that local hospital infrastructure and physician preference play a large role independent of national guidelines.¹²

Efforts to close the gap have included pacemaker reuse programs, where devices explanted from deceased patients in wealthy countries are sterilized and shipped to developing nations. The idea makes intuitive sense, as modern pacemaker batteries last years, and many have substantial life remaining at the time of explant. But the logistics, infection concerns, regulatory hurdles, and liability questions have kept these programs small and controversial.¹³

Complications and Costs

Pacemaker implantation is a relatively safe procedure, but “relatively safe” does not mean risk-free. A retrospective study from a resource-limited setting found that about a quarter of patients experienced at least one complication over 10 years, with lead dislodgement being the most common (affecting about 7% of patients), followed by pacemaker-induced tachycardia and early battery depletion (each around 5.5%).¹⁴ That study also found that older age, being female, and having a dual-chamber device were each independent predictors of complications.¹⁴

Generator replacement procedures carry their own risk. Data from the REPLACE registry showed that major complications occurred in about 4% of straightforward pacemaker or defibrillator replacements, but climbed to nearly 19% when the procedure included upgrading the device or adding new leads.¹⁵ Six-month infection rates hovered around 1% to 1.4%.¹⁵ These numbers matter because most pacemaker patients will eventually need at least one generator change during their lifetime, since batteries typically last 7 to 15 years depending on usage.

The financial toll of complications is substantial. A nationwide economic study in Europe found that the average three-year cost of managing a pacemaker complication was roughly €6,700 per patient, with pocket bleeding being the most expensive complication type at about €7,100.¹⁶ In the U.S., infection-related complications have historically been among the costliest, with one older analysis putting the mean cost of a pacemaker infection at nearly $24,500, well above Medicare reimbursement for many patients.¹⁷

How Pacemaker Technology Has Shifted

The devices going into patients today look very different from those of even 20 years ago. One of the clearest shifts has been the move toward dual-chamber pacing. By 2009, about 82% of all U.S. pacemaker implants were dual-chamber devices, up from 62% in 1993, while the simpler single-chamber ventricular pacemakers dropped from 36% to 14% of implants.² Dual-chamber devices pace both the atrium and the ventricle, which more closely mimics the heart’s natural rhythm and tends to reduce symptoms like pacemaker syndrome, a condition where single-chamber pacing causes the heart’s chambers to contract out of sync.

The most exciting recent development is the leadless pacemaker, a self-contained capsule the size of a large vitamin that is threaded into the heart through a vein and anchored directly to the heart wall. By eliminating the leads (wires running from the device to the heart), leadless pacemakers sidestep some of the most common complications of traditional systems. A large meta-analysis pooling data from over 33,000 patients found that leadless devices were associated with significantly fewer overall complications, major complications, hospitalizations, re-interventions, and device dislodgements compared with conventional transvenous pacemakers.¹⁸ Long-term data are still being gathered, but the early track record is encouraging enough that leadless devices are becoming more common in clinical practice, especially for patients at higher risk of infection or those with limited venous access.

Remote Monitoring and the Digital Shift

Modern pacemakers can transmit data wirelessly to a clinician’s dashboard, allowing heart rhythm, battery status, and lead integrity to be checked without an office visit. Remote monitoring has been endorsed by professional societies for years, yet adoption has been slower than you might expect. Among U.S. Medicare beneficiaries, remote monitoring claims for pacemakers grew by about 61% between 2012 and 2015, but even by the end of that period the average pacemaker patient was still only completing about one remote check-in per year.¹⁹ In-office visits declined slightly but remained the dominant mode of follow-up. Total annual spending per patient actually dropped modestly (by a few dollars) as remote checks offset some in-person costs.¹⁹

A variety of patient-side and system-side barriers have slowed remote monitoring uptake. Some patients find the bedside transmitter cumbersome, forget to plug it in, or move out of Bluetooth range. Newer systems that pair directly with smartphones aim to solve these problems by removing the extra hardware. Cleveland Clinic researchers have reported that direct smartphone-based pacemaker monitoring achieves high transmission success rates, addressing a longstanding complaint about patient adherence.²⁰ The COVID-19 pandemic gave remote monitoring a significant push: with in-person visits curtailed, many clinics that had been slow to adopt the technology were forced to implement it almost overnight.²¹

What the Pandemic Did to Implantation Rates

COVID-19 disrupted pacemaker implantation volumes in a pattern that played out in hospitals around the world. Croatian data offer a detailed snapshot: during April and May 2020, pacemaker implantations dropped by roughly 45% compared with the same months in 2018 and 2019, and a similar dip occurred during the November 2020 wave. But what followed was unexpected. During the summer months of 2020, implantation rates surged to about 48% above the pre-pandemic summers, as hospitals worked through the backlog of deferred cases.²² Over the full year, total implant numbers nearly evened out, suggesting that most patients eventually received their devices but faced potentially dangerous delays. The short-term deferral of a pacemaker in someone with symptomatic heart block or severe bradycardia carries real risk: fainting, falls, and in extreme cases, cardiac arrest.

Pacemakers in Children

Pediatric pacemaker implantation is rare but not unheard of. French national data spanning 2014 to 2024 identified 774 pacemaker implantations in children under 18, with the annual rate declining from about 6.5 to 3.9 per million of the total population over the period. The two leading reasons were congenital heart block (about 46% of cases) and heart block arising after surgery for congenital heart disease (34%).²³ A 25-year single-institution series found a similar breakdown, with high-degree heart block accounting for about 65% of pediatric implants and sinus node dysfunction explaining another quarter.²⁴

The downward trend in pediatric implant rates in France likely reflects improvements in surgical techniques for congenital heart disease (leading to fewer cases of surgically induced heart block) and more conservative thresholds for when to implant. Updated pediatric guidelines have actually lowered the heart rate cutoff at which a pacemaker is recommended for children with heart block, explicitly aiming to reduce too-early implantation.²⁵ Children who receive pacemakers face a lifetime of device management: multiple generator changes, lead revisions as they grow, and the physical and psychological weight of living with an implant from a young age.

Life After Implantation

For most recipients, a pacemaker transforms daily life. Symptoms like dizziness, fainting, and crushing fatigue often improve quickly after the device is placed. Research on quality of life after implantation consistently shows short-term gains in physical, psychological, and social well-being.²⁶ The picture gets more complicated over the long haul: some studies find that the initial quality-of-life boost diminishes with time, as patients adapt psychologically to the device and occasionally encounter device-related issues like lead fracture or pocket discomfort.²⁶

Survival data, though mostly drawn from older studies, paint a reassuring picture. Even in patients over 70, early research showed one-year survival rates of about 90% and five-year survival rates of about 58%, figures that were surprisingly close to younger pacemaker populations in the same era.²⁷ Modern devices, better patient selection, and improved periprocedural care have likely pushed those survival numbers higher, though long-term follow-up studies with contemporary devices in large populations remain an active area of research.

How Surgical Technique Affects Outcomes

One detail that rarely comes up in patient-facing discussions is that the approach a surgeon uses to access the vein can influence complication rates. A large analysis comparing two common techniques found that threading the lead through a small incision in the cephalic vein (a vessel on the outer part of the upper arm/shoulder) resulted in significantly fewer complications than puncturing the subclavian vein (the large vessel under the collarbone), with perioperative complication rates of about 2.5% versus 3.6%.²⁸ The subclavian approach carries a small but real risk of pneumothorax (a collapsed lung) that the cephalic technique avoids. In practice, the cephalic vein is not always large enough to accommodate the leads, so surgeons sometimes have to use the subclavian route anyway. Still, the data suggest that when the cephalic vein is viable, it tends to be the safer option. If you are scheduled for a pacemaker, it is a reasonable question to raise with your electrophysiologist.